Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Ulsan University Hospital.
Recruitment status was:  Enrolling by invitation
Information provided by (Responsible Party):
Young Joo Min, Ulsan University Hospital Identifier:
First received: January 18, 2013
Last updated: December 10, 2013
Last verified: December 2013

Lung cancer is the leading cause of cancer-related death worldwide and is well known to remain a major health problem. Non-small-cell lung cancer (NSCLC) constitutes more than 80% of all the cases of lung cancer.

Today, NSCLC can be defined by various molecular criteria. Especially, somatic mutations within the epidermal growth factor receptor (EGFR) gene itself were discovered in a subset of NSCLC patients.

Two activating EGFR mutations are in-frame deletion in exon 19 and the substitutions for L858R in exon 21, which account for 85% of all clinically important mutations related to EGFR TKI sensitivity.

Besides two activating EGFR mutations, other EGFR mutations in NSCLC have been discovered. G719 and L861 are reported to have intermediate sensitivity to EGFR TKI. And in-frame insertions within exon 20 and T790, which are known to be resistant to EGFR TKIs.

However, there are still other EGFR mutations such as E709 and S768 as well as doublet EGFR mutations are also observed. These rare mutations have not been fully described and data on their correlation with response to EGFR-TKIs are still unclear.

Research hypothesis Rare EGFR mutations of unknown clinical significance in NSCLC patients, which are distinguish from mutations such as deletion in exon 19, L858 and insertion in exon 20, have some possibility of EGFR TKI sensitivity.

Rationale for conducting this study It has an opportunity to be shown the efficacy of EGFR TKIs in patients with rare EGFR mutation in large number of patients in Korea (Asia) during the short period.

Lung Neoplasms

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Efficacy of EGFR Tyrosine Kinase Inhibitors (EGFR TKIs) in Patients With EGFR-mutated Non-small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L859R: A Retrospective Analysis

Resource links provided by NLM:

Further study details as provided by Ulsan University Hospital:

Primary Outcome Measures:
  • the efficacy of EGFR TKIs as defined by objective response rate [ Time Frame: up to 1 year ]

Secondary Outcome Measures:
  • the incidence of patients with rare EGFR mutated NSCLC [ Time Frame: up to 1 year ]

Other Outcome Measures:
  • the clinical characteristics of patients with rare EGFR mutated NSCLC [ Time Frame: up to 1 year ]
  • the efficacy of EGFR TKIs as defined by disease control rate, progression-free survival and overall survival in the patients with rare EGFR mutated NSCLC [ Time Frame: up to 1 year ]

Estimated Enrollment: 90
Study Start Date: March 2013
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
comprehensive cancer hospital

Inclusion Criteria:

  1. Histological confirmed non-small cell lung cancer (NSCLC), Stage IIIB or stage IV, between January 1, 2008 to December 31, 2011
  2. Confirmed EGFR rare mutations (EGFR mutation except both exon 19 deletion and exon 21 L858R) using direct DNA sequencing
  3. Experiences of treatment with EGFR TKIs.
  4. at least one measurable and/or evaluable lesion according to RECIST criteria (version 1.1)

Exclusion Criteria:Subjects should not enter the study if any of the following exclusion criteria are fulfilled: EGFR wild type, EGFR exon 19 deletion alone, EGFR L858R alone

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01775943

Korea, Republic of
Ulsan University Hospital
Ulsan, Korea, Republic of, 682-060
Sponsors and Collaborators
Ulsan University Hospital
Principal Investigator: Young Joo Min, M.D. Ulsan University Hospital
  More Information

Responsible Party: Young Joo Min, Professor, Ulsan University Hospital Identifier: NCT01775943     History of Changes
Other Study ID Numbers: ISSIRES0070
Study First Received: January 18, 2013
Last Updated: December 10, 2013

Keywords provided by Ulsan University Hospital:
Epidermal growth factor receptor
Lung cancer
Drug sensitivity

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases processed this record on April 28, 2017